[Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia].
Apart from on-label indications, recombinant factor VIIa (rFVIIa) is increasingly administered for treatment of life threatening bleeding events when appropriate standard therapy fails. Case reports and short treatment series document the efficacy and safety of rFVIIa to achieve haemostasis in patients with platelet function disorders and thrombocytopenias of various origin. An established on-label indication for the use of rFVIIa is given in patients with Glanzmann thrombasthenia with refractoriness to transfusions of platelet concentrates. Bolus applications of rFVIIa at dosages between 80 and 120 microg/kg body weight every 1.5 to 3 h are also administered successfully in patients with Bernard-Soulier syndrome, platelet storage pool defects, and other acquired platelet function disorders. In patients with Glanzmann thrombasthenia, at least three bolus injections are required to achieve effective haemostasis. In approximately half of the patients with thrombocytopenias, a single bolus of rFVIIa has been shown to be sufficient in managing otherwise untreatable bleeding complications. In these patients, haemostasis was achieved even at platelet counts <20,000/microl, although the efficacy of rFVIIa increases at higher platelet concentrations.
Zotz
R B
RB
Institut für Hämostaseologie und Transfusionsmedizin, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225 Düsseldorf. zotz@med.uni-duesseldorf.de
Scharf
R E
RE
D001791:Blood Platelet Disorders / Q000188:drug therapy*; D015942:Factor VIIa / Q000627:therapeutic use*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000188:drug therapy*
D011994:Recombinant Proteins; D015942:Factor VIIa